Clinical trials located in

El Palmar

El Palmar city is located in Spain. Currently, 3 clinical trials are being conducted in this city.

  • CT-EU-00118835

    Study on the safety and effects of Vonafexor in patients with Alport Syndrome

    This study focuses on Alport syndrome, a genetic disorder affecting the kidneys. The therapy being tested is Vonafexor, a medication identified as EYP001a. The purpose of this study is to evaluate the safety of Vonafexor and its effects on kidney function in patients with Alport syndrome who are at risk of disease progression.

    The study involves a single group of patients who will receive escalating doses of Vonafexor over a 24-week treatment period, followed by a 12-week follow-up period. The main goals are to assess the safety of the drug and observe changes in kidney function and other renal biomarkers.

    • Vonafexor
  • A study comparing biosimilar nivolumab and nivolumab in the treatment of resected melanoma

    The aim of this study is to test whether a new drug called ABP 206 (biosimilar nivolumab) works as well as the approved cancer drug OPDIVO® (nivolumab) in people with advanced cutaneous melanoma that has been surgically removed. The study divided people into 3 groups: one group will receive ABP 206, the second will receive real OPDIVO® approved in the US, and the third will receive the version of OPDIVO® approved in Europe. All of these medicines will be given through an intravenous drip every 4 weeks for up to 1 year, or until the cancer comes back or gets significantly worse.

    The main goal is to check whether ABP 206 (biosimilar nivolumab) is absorbed and maintained in the body in the same way as OPDIVO®. Researchers will also closely monitor how well it works, what the side effects are, and whether the body produces antibodies against it. The entire study will last approximately 13 months for each person joining.

    • Nivolumab biosimilar
    • Nivolumab

See more clinical trials in other cities in Spain:

.